Nasdaq · Industrials
OptimizeRx Corp (OPRX)
As-reported financials and recent SEC filings for OptimizeRx Corp, latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$109.4M
Net income
$5.1M
Net margin
4.7%
Diluted EPS
$0.27
ROE
4.0%
P/E (TTM)
—
Market cap
—
Debt / equity
0.2×
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $109.4M | $92.1M | $71.5M | $62.5M | $61.3M |
| Gross profit | $73.6M | $59.4M | $42.9M | $39.0M | $35.6M |
| Operating income | $11.7M | $-13.7M | $-26.4M | $-12.3M | $361,100 |
| Net income | $5.1M | $-20.1M | $-17.6M | $-11.4M | $378,079 |
| Diluted EPS | $0.27 | $-1.10 | $-1.03 | $-0.64 | $0.02 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
8-K2026-06-12
View on EDGAR →42026-06-10
View on EDGAR →42026-06-10
View on EDGAR →42026-06-10
View on EDGAR →42026-06-10
View on EDGAR →42026-06-10
View on EDGAR →42026-06-10
View on EDGAR →42026-06-10
View on EDGAR →Largest Industrials peers
Go deeper on OPRX
Search OptimizeRx Corp’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeOr check your whole portfolio free — no account needed.
Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.